Bayer

Leaps by Bayer Announces One of the Largest Global Surveys of Society’s Attitudes Toward Breakthrough Technologies

20 Jan 2025

Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances

15 Jan 2025

First participants randomized in AskBio Phase II gene therapy trial for Parkinson’s disease

14 Jan 2025

BlueRock Therapeutics advances investigational cell therapy bemdaneprocel for treating Parkinson’s disease to registrational Phase III clinical trial

13 Jan 2025

Bayer submits application to U.S. FDA and to China’s CDE for new indication of finerenone for patients with common form of heart failure with high unmet medical need

10 Jan 2025

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies

10 Jan 2025

Bayer Acquires Camelina Assets from Smart Earth Camelina Corp. to Advance Biofuels

09 Jan 2025

Elinzanetant meets all primary and secondary endpoints in Phase III study OASIS 4 for treatment of moderate to severe vasomotor symptoms caused by breast cancer treatments

09 Jan 2025

Bayer and Neste to Collaborate on Developing Feedstocks for Renewable Fuels

08 Jan 2025

Vividion Therapeutics Acquires Tavros Therapeutics to Expand Functional Genomics Capabilities and Boost Drug Discovery Platform

08 Jan 2025

View details about the software product Informachine News Trackers